UK's Post-Brexit Medicine Plans Under Pressure
Time Is Tight For Talks To Seal A Deal With EU
Executive Summary
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
You may also be interested in...
Industry Presses EU To Agree Medicines Deal With UK
A letter addressed to EU leaders has urged them to prioritize the preservation of supply chains and access to medicines for patients in both the UK and the EU as worries grow over the sluggish pace of talks on a trade deal.
Industry Presses EU To Agree Medicines Deal With UK
A letter addressed to EU leaders has urged them to prioritize the preservation of supply chains and access to medicines for patients in both the UK and the EU as worries grow over the sluggish pace of talks on a trade deal.
Drug Price Impact of UK-US Trade Deal Comes Under Scrutiny
A month after the UK and the US began talks on a future free trade agreement, a new House of Lords committee says that an FTA involves risks as well as benefits, and has stakeholders to give their views on the likely impact of a deal in areas like drug pricing and the NHS.